ArticleSensors (Basel, Switzerland)2026
A Novel Convolutional Neural Network for Explainable Diabetic Retinopathy Detection and Grade Identification.
Article in Sensors (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic retinopathy represents one of the leading causes of blindness worldwide, making early diagnosis essential for effective clinical intervention. We propose an explainable method aimed at automatically identifying the severity levels of diabetic retinopathy in retinal images using deep learning. The proposed method considers several convolutional neural network architectures, i.e., VGG16, StandardCNN, ResNet, CustomCNN, EfficientNet, MobileNet, and a novel architecture, i.e., FGNet, specifically designed and developed by the authors for diabetic retinopathy detection. The proposed network achieves an accuracy of 0.75 when trained for 10 epochs and 0.71 for 20 epochs. Explainability behind model prediction is further supported through Gradient-weighted Class Activation Mapping, providing visual insight into the learned decision-making process and potentially supporting early clinical assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.